0001193125-11-060555.txt : 20110309 0001193125-11-060555.hdr.sgml : 20110309 20110309134622 ACCESSION NUMBER: 0001193125-11-060555 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20110308 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20110309 DATE AS OF CHANGE: 20110309 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cardium Therapeutics, Inc. CENTRAL INDEX KEY: 0000772320 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 840635673 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33635 FILM NUMBER: 11674513 BUSINESS ADDRESS: STREET 1: 12255 EL CAMINO REAL STREET 2: SUITE 250 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 436-1000 MAIL ADDRESS: STREET 1: 12255 EL CAMINO REAL STREET 2: SUITE 250 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: Cadium Therapeutics, Inc. DATE OF NAME CHANGE: 20060118 FORMER COMPANY: FORMER CONFORMED NAME: CARDIUM THERAPEUTICS, INC DATE OF NAME CHANGE: 20060118 FORMER COMPANY: FORMER CONFORMED NAME: ARIES VENTURES INC DATE OF NAME CHANGE: 20000523 8-K 1 d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

DATE OF REPORT (Date of earliest event reported): March 8, 2011

001-33635

(Commission file number)

 

 

CARDIUM THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   27-0075787
(State of incorporation)   (IRS Employer Identification No.)

12255 El Camino Real, Suite 250

San Diego, California 92130

   (858) 436-1000
(Address of principal executive offices)   (Registrant’s telephone number)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

ITEM 8.01 OTHER EVENTS.

On March 8, 2011, Cardium Therapeutics, Inc. (“Cardium”) issued a press release announcing the publication of positive findings from the Company’s Matrix Phase 2b clinical study. The clinical paper titled, “Formulated Collagen Gel Accelerates Healing Rate Immediately after Application in Patients with Diabetic Neuropathic Foot Ulcers” is to be published in Wound Repair and Regeneration, an official journal of the Wound Healing Society and is now available online at http://dx.doi.org/10.1111/j.1524-475X.2011.00669.x.

 

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits.

 

99.1

   Press Release of Cardium issued on March 8, 2011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    CARDIUM THERAPEUTICS, INC.
Date: March 9, 2011   By:  

/s/ Christopher J. Reinhard

    Christopher J. Reinhard
    Chief Executive Officer
 EX-99.1 2 dex991.htm PRESS RELEASE Press Release

Exhibit 99.1

LOGO

Press / Investor Contact:

Bonnie Ortega

Director, Investor/Public Relations

Cardium Therapeutics, Inc.

Tel: (858) 436-1018

Email: InvestorRelations@cardiumthx.com

POSITIVE FINDINGS FROM EXCELLAGEN MATRIX CLINICAL STUDY

PUBLISHED IN PEER-REVIEWED JOURNAL

WOUND REPAIR AND REGENERATION

SAN DIEGO, CA – March 8, 2011 - Cardium Therapeutics (NYSE Amex: CXM) today announced the publication of positive findings from the Company’s Matrix Phase 2b clinical study. The clinical paper titled, “Formulated Collagen Gel Accelerates Healing Rate Immediately after Application in Patients with Diabetic Neuropathic Foot Ulcers”, to be published in Wound Repair and Regeneration, an official journal of the Wound Healing Society, is now available online at http://dx.doi.org/10.1111/j.1524-475X.2011.00669.x.

Findings of the Excellagen Matrix 2b Clinical Study

Cardium’s highly-refined collagen-based topical gel wound care dressing (Excellagen™ 2.6% collagen formulation) was evaluated in the controlled, double-blind randomized Matrix Phase 2b clinical study for the treatment of chronic non-healing diabetic lower extremity ulcers. Analysis of the data found Excellagen to be safe and well tolerated, demonstrated improved wound area reductions and wound closure incidences at 12 weeks following only one or two treatments, and showed a statistically significant acceleration of wound healing during the first week following a one-time application compared to patients receiving standard of care therapy. In the first week following treatment, the radius of Excellagen-treated wounds decreased on average by 0.20 cm compared to 0.08 cm for standard of care-treated wounds (p<0.05).

From the perspective of planned commercialization, the data were especially encouraging in that the observed treatment effect was particularly evident in patients with larger-sized wounds (>3.0 cm2), which are often very difficult to treat and can ultimately lead to amputations. For example, at 12 weeks, 45% of all Excellagen-treated wounds achieved complete closure, compared to 31% in the standard of care group, representing a 45% overall improvement. Based on safety data and the immediate acceleration of healing, the authors suggest that more frequent applications of Cardium’s Excellagen product candidate hold promise to significantly improve overall incidence of complete wound closure.

“The publication of these positive clinical findings from the Excellagen Matrix 2b clinical study together with recently-announced preclinical research demonstrating that Excellagen activates platelets and release of platelet-derived growth factor (PDGF), which plays a critical role in the wound healing process, provide us insight into the significant and rapid healing response to Excellagen. The Company and the researchers believe that multiple treatments of Excellagen over

a 12-week treatment period may provide an opportunity to sustain accelerated healing rates and enhance the wound management process for patients suffering with non-healing chronic diabetic foot ulcers. We look forward to the commercial market launch of Excellagen, upon clearance by the FDA of our pending 510(k) application, and to the development of new product extensions based on our custom formulated collagen platform,” stated Christopher J. Reinhard, Cardium’s Chairman and Chief Executive Officer.

About Wound Repair and Regeneration

Wound Repair and Regeneration is the official journal of The Wound Healing Society, The European Tissue Repair Society, The Japanese Society for Wound Healing, and The Australian Wound Management Association. Wound Repair and Regeneration provides extensive international coverage of cellular and molecular biology, connective tissue, and biological mediator studies in the field of tissue repair and regeneration and serves a diverse audience of surgeons, plastic surgeons, dermatologists, biochemists, cell biologists, and others. Additional information about Wound Repair and Regeneration can be found at the following web link: http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1524-475X.

About Cardium

Cardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, partnering and other economic monetizations. Cardium’s current investment portfolio includes the Tissue Repair Company, Cardium Biologics, and the Company’s in-house MedPodium healthy lifestyle product platform. The Company’s lead product candidates include Excellagen™ topical gel for wound care management, and Generx® DNA-based angiogenic biologic for patients with coronary artery disease. In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company’s biomedical investment portfolio. News from Cardium is located at www.cardiumthx.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that manufacturing changes and modified regulatory submissions will be efficiently and effectively accomplished and that the U.S. Food and Drug Administration will grant marketing clearance of our product candidates such as Excellagen; that we or a partner can successfully introduce our products into advanced wound care markets; that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or procedures; that our product candidates will be perceived as being sufficiently safe and effective to lead to product advancement or partnering; that our product candidates offer the potential for simpler or more cost-effective treatments for physicians and patients than other products that currently are or will be on the market; that FDA or other regulatory clearances or other certifications, or other commercialization efforts will be successful or will effectively enhance our businesses or its perceived value; that our

products or product candidates will prove to be sufficiently safe and effective after introduction into a broader patient population; that discussions with potential strategic partners will be successful or that any partner will be able to efficiently and effectively commercialize our products in U.S. or international markets; or that third parties on whom we depend will perform as anticipated.

Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of biologics and other therapeutic products and devices, and in the conduct of human clinical trials and other product development efforts, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition and regulation, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2011 Cardium Therapeutics, Inc. All rights reserved.

For Terms of Use Privacy Policy, please visit www.cardiumthx.com.

Cardium Therapeutics™ Generx® and MedPodium™ are trademarks of Cardium Therapeutics, Inc.

Tissue Repair™, Gene Activated Matrix™, GAM™, Excellagen™, Excellarate™,

Osteorate™, Appexium™, Cerex™, and Linée™ are trademarks of Tissue Repair Company.

(Other trademarks belong to their respective owners)

GRAPHIC 3 g160368g28y30.jpg GRAPHIC begin 644 g160368g28y30.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`00$B`P$1``(1`0,1`?_$`-<```$$`P$!`0$````` M```````'"`D*!`4&"P(#`0$!``(!!0$!``````````````$"!P,%!@@)!`H0 M```'``$#`@,"!0H2"04```$"`P0%!@<(`!$)$A,A%`H5%C$B-ADY03(C,[56 MUA=8F%%B8S34-766MC=7=Y?7&'A9&F%Q"=#88HL)#-$14E-0E-5;_V@`,`P$``A$#$0`_`+_'1$VKD_RZP+A[ M1!O^\7MC5F#GYI*O0+<@R=PN4@T1!92+J5:;"+^6=%`Y`44[)M6WN$,X61(8 M#=;=D\M88B#[Q?/#6^`YNY&W@=+>,DFEPB8]PHHF*'R%\F_DI,$]QVAX3@EQ4DOG$([ M9+M"M+UL%V9IJ>P+ZF0S\&\61%15$Q`<-T46J)O6"<@X.3L'%8+_`')N+ZS' MAMCBSRD<-4CO:TN.DXLVF^2&A\A>65R!-R9[/;+L5N+'"] M=H-6RSJ(KE/?UQI#%*BS3*F4%5C@4H`8YP`H!N3-I8]Y#\C)<74WB9)'4K[` MTBBQ)?\`?1U3QT;\?TIQ>V-E8*K0R'%XRVUZ&ES@V6>Y9.Z7BYQ)TM!)J&M) M->RL'A]\>),463*8IU^TJNRD>JV-ZVTJV596\&ZLXBIV-\XND MLN"/;P=S]IXK8<9WS=S^.EUR;E-Y`9"]\5U M9V$\;P[@Z-P?;:A"1P])CFL`)#0*E(E9^"?.+CN'WFX,OE6T_"+*J%`J`G*GZ3&$3NB>HQNOBDPF:Q_UN$O7O:/^ MRG]]I]@=S'\N*R#B.XWMYZHG^$]Q73W'65U/0.S6VVFPNXW#@))+/4Z&4`<7 MT)J``V%U`$<;/,#4K%IX\:>:.:2G$'DBQ?-(,["TNO>S*TS3I)HU.,UNW[4Q#[81AD\7.6UC:"1,_US M!="$=$1T1'1$=$1T1'1$=$1T1'1$=$1T1'1$=$1T1'1$=$1T1'1$=$1T1'1$ M=$1T1'1$=$1T1'1$=$1T1-:YD\KZ!POP2W;E?RFD$X8B,95*FV=I-)6]723! M4D#4XI94BI45GRB1U5UQ(^I-CT[VT?2=.3)C-:E@YK:_I6*TA_"W22HUPM=7!"=/GD#'P4#81;YG M16*_NR(.#HJS\HG7_+'V8XI][U'%DRZRMVR6UCN[6WN*PB]F?--#JO[Q[= M,&@/;9VX!8V,N@X>R_N=VI@;S<^>VE>08/'VTEQ<2B>RD].&)I=(_1%05DII=HZ?$8LHR! MCI:6F>)N,MEX+^29\<;:N>UK07ZG$^Z#0T:!^>2 M\:7\J>M?WE:I_`3K:O\`-VW?_--_JO\`[*SA_P`B'=G_`/C;O_U6._\`>)@7 M/?9O$]Y'Z/$4!CR3JT=R$;/&\/A=YCL\TY:7+:)QXDSBZ+,A]Q$E)>FVN7UMPP"`7#1?UI&X,?74>33[O%KCS'AS'%=E^VS M87>EVJ[AGW+<;3O9>F+V.ER]H^]L!%]WA:727<7^,(BNK:)KGLD`^L:TPR`L M<-*9>'SR#:+G6G2'CGY@O)AKM3L',I7['6_F6\CCUBF'2XK2C5 M=-J"E9=B)Q.F'RP'.11F!?EVEG[BWN3M[+$B9KBV,NY@CG&3X_L'YO$+EW?- MVQ[6W3M"+NGZ&QP/P-W;,N\E#;MTQS03Z7,R<$312-P+M-_'PHX^MI:YDY-H M'K):\@D"(``B(]@#XB(_```/PB(]$32[ISWX.YQ8'=4OW,+C'3;.P[_/UZR[ MGFD/,L1!==L8CV-?65%VU5(X;*$$BA"F`Q!`0Z5"G2[R*Y3\YCXZOY=?$;^< M-E/\*>HJ%.EWD5]I>2WQW+JI((\Y^)*JRZJ:"*2?(3*SJ*K+'*DBDF0MI$QU M%5#`4H!\1$>P=*A-+O(I[8"!@`Q1`2F`!`0'N`@(=P$!_5`0ZE57]Z(D.IO) MOCEHNE6C&:!O./W;7*3]K_?',:IH]1L%]JWW?D6\//!/U.+EG4Y$C"RSM)J[ M!=`@MW"A4U/2<0#HIH1Q\$N/10N1OE^HV6U">T'2KA6:!1*LR&2LMRN4W&UN ML5^/!5)`7TS.2[AI&QK0%UB$]Q90A/48`[]Q#HB:=^CY M_D=-F]$U.[53.:#6D6SBQ72[S\75ZM!(/'S6,:+2\]-.F<9'I.9%ZB@F954@ M'65(0.YC``E%*\DU3\YCXZOY=?$;^<-E/\*>HJ%;2[R*/SF/CJ_EU\1OYPV4 M_P`*>E0FEWD5M(7R+\`;'*,X2!YM<49:7D#J)L8YCR`RQP[=J)(JN%"((DM( MG4.5!$QNP?'L4>IJ%&EWD4[Z.DHZ88M92(?LI2,?(DH1F(W'8H9U86,OEE8U"F3F@Q MCRI+*-K2U?U"-F7,\T<5UPD8CXBB!3-3E$%`*(=%-#2M."^K!RSXNU366."V M?D3B=>V^4D8&(C^?L7,JU5;$52(8AETS$`1,40Z*0">2VNS4C`DS11)-N+@$?7[(+IB?MZR]R`$ M\DKL1+Q-@BHR=@9..FX.:8,Y6'F8AZVDHJ6BY!NF[8249(LU5FC]@^:JD516 M2.=-5,P&*(@(#T4+8]$1T1(EL_)7COQR;0+S?]SR3$VMI5DD:TXU70JK0D9] M6'2;+RR<,I9Y2,+)'C$7J)G`(B?V2JD$W;U%[E(!/)=M_&7G?[^JC^1'\9?Y M0Q7^+O\`?U_77Y(_^8_UI_3]$H53O\T>TVOEYSWHO$7-7RCR)S*=K.304:*I M@BW^U:4^BT[%-+D244*N6#:24?&B<2`H@+5V4H=E!]6'MXWDN6SC,3;FK(W! M@'@9'D5/S5`^8KWR[!M@87H?VV9'K=NR,1WN7MI\E,^@]1F*L&2&"($@4]9T MJ0[]XE M>:'23NSW%LON=N>O.XA);NYV9.%IXNL;E[?JX@3359M9`^W:30_=V1EP# MBX4.M!H%TRF\6O-=$KSVJ7RCS+JOVFMR7M_-Q,LS](G0.HB=1NY0624(J@ND M/3@%X[>0W`O(IQMF%8 MN-LL5:CU]#TQI(R3'6:SL<65?[Q%8VQBY93]/DZG/.3?9S=#V6X-4VJWH7(8 MBJF7,!@MOW^#B>(FOE\L,+:W;Q96#F1OQMQBY*>AKMGM?#=1W,+1Z[WZG^HZ9FJ-P31S7X,YB8&M#^+0?I/(Y%SJ"I/#AP`XKJ9MGN'ZA[ M`P&4P'3.:/;;,SDGW5W-8:HKE\="+>R9.YSY(;2UURNB9&YLCG2DRR/TLI2E M\KM#XUYGS6T6E\7$(V.H\+&0"%LK]>5(XJ57TX4W0VZOU9?ZPNEEW%<33&VFG!;XF!7-;H+O_`+TZ:'`_<<>^A>)*'W9[QOU<<9%6VYED=IU0ERW?4-<=W5!U+% M.8]!(M`R%I6;4.X3L.4[9Y'Z#20&R9M;!=$'TI2RD0T<-TU?UW_A2`#^`.OM MW]CS!=0Y>#W7.]UQ'@]O%COEI4?[(6/?PO\`JC#N79VX.A.Y2VYMK-KKRVAE MHYK[*[^HO[;2><8DU+*)C9)FN%@KZW(HF MH=IH%275KMM!0$DT2)%D)2/,]1(!0]+9TGUSW!9$97%0WA^TV!&#_"8+OUK-Q!`=97($]M2I).B-XB<:\7QO46/U.NV: M=BOBSM*F76R6I/<-7L8$Z-819NCIG M[JL%ET!_%5$0W9W)8,B`+N*BD\-_T\WCXY:>/S$.3W(*/U>Y:)M*-NGWK6$T M.0HM;JS."OEIIK&&A(RKHM%G@*M:Z1PXLAG]+=XCF+QD_;YOL97#!ZT?MC&W>^'* M5PR<).D#&(+SLH]6(R$*F0B9?@4A2D+W^/XI0`H?']7X M!U*TU!QYY/*2P\;G$J0:428:$Y0;VSG:3A[`JI%'E10(S31M^QO&@"(@QSUE M(I&9>X'MN)MPS3$JB8+%"":*[&ZC[%32>\#>?7B6Q;A7YD(.0ERW^=N[NV:Q M49,DD$S0(6^O4%Z/$:\[*L:3EX7>*P[>M+,*WI/&/Y-LW5[N#"VH01OS6@06FA3+_/$`&\0?/(#`!@'%5>X"`"`_^JZS^$!^ M'4'DK,^,*K+]/QX9.#'D6XE:GL/)NFWZ-GC[B6_P#%,-5I]TL6ZQ.:O8Z>T=Y:(Y-@XI%\ MN!++".Y)J%IA+/'2=6:D37;/RH%2-^U%5[*#!%%>-Y<:%2[\L=8O.[?2BN-5 MT^<<6N^W'BI@CJU62056=2-AE(_9,UAU)F6=.EG"[V8DR1I5GBYSB99R0&AYTV>573;-38P*S7*Y0 MI.+0-$0JZ+0[M-U87(G6$!.<#%`1[%#H`"%+WN:Z@4VO_*R^(C_)MLO^GF^_ MV9U-`J^H]<9H/THGBPM%1F(6FL=US6S.VJI8:XQVL25K/$OP24!JLZKMT9S< M'+L"KB4RR!DTE%"%])%DA'U`TA!*Y1-_2B\@MEI?+#D_P.F+@\M&+P%'NU_A MH1Z[>JQ=2T'-=-KV=R\O26+M1?[#BKU'3_N/VA!(F95DW4[>Y[ICPWG17E`T MZO%(SXATTR_4\@UU9:".B+SY?JPDTS^3/A MN)R$,(<>L[`!,4IA#_\`8J^_@$0'JKN:UX_A*=5]92"7V'X]3K`02)S?)LPF M.4!`A0BL2$QOB`]@``^/1RB+Q6?]--Y2)VARL?XI.61Y&I6.,;IRG%*6N";I M@_&/GXI&\EQ&4.\4.4@.Z]+DFZ>H()HN(U4[,AC&^134`^"2-^D%=AZLM%)E ML^QYOQ\RF_[;K]I84O,\QK$I;[G9I(3BVBX6);F77.1%$JCEZ]<&`J+9LB0Z M[IPH1)(AE#E*)2!4T"\G/RQZYGQMK#U-<];JE, MHZ<2ZEH-BZ4.JU?WITE8HR5M*J)C$+(22:1/2W3;IDH>*^EH#13Q7H/=@_H! M^A$[?@#\']#_`*NK?J6C_:5?GQ9BIR+\L^>Z%:.ZKR4N^O[D]1DEU';@\LC` MVB;CTS.VJ;,KAZPE)9!0%#)D2.+<1$@=P#K"&V/_`)#=4=Q)S+Y)./'C1Q'' MV$C\B_1OWBZ.EO95E-L8?W8(1OQ:Y/SMKQK+''CLUY"03%1.M:@SBTCI6-%NU,1C5=(0;$3= M3M=]PA"(.0$SV+`1,W]1!.@KQC<.V;7.1^HVD=^T<'TY^37^8\CS'AY'N/VK M]XF].W+*#$W0ERW3"YD!GQ[I"#`7.J^XL2XEL,]"2^.@BN.`DH[3(RN5P[P; MR)<%>2UMDG#Z-XU9WFJ;62W_`$S7W3E;C-/T,7#AHP.5=LNT+HTU83$42KR$ M,*AO*!SQ1P=]QBAJUUZ^Z!M?2U.:)3H2<0%)W+\)E_Y!.('9N5D?.YQB M#@0EXF@.3.X?2M517!51NZ?B7N<_GKF:\S5Y,^6>>5Q?)+(\ESWOSLIV/:`Y.=XU;W>G1?S!SM#*F(V M8N'];5,D8I"@HM[W<3"`]MJZ>3%V/G@)X,FJ/]IH_-4?I6;OQ5]OPV?53;6Y MHV.$M_@'PO=I`:YUI=2:0'4JY[63M#@2=+?3H`#QX?ZL?]%I"_[UF+_N+H?7 M/W5]/-^APX3?\`TCHW_P";=,ZD;\<< M@T;==>L3:J9KE=4EKE<)UT("#2)B&YECHM4!,0SV4D%O0V9MB#[KITJFD0!. MTKSZ>4;0_)/R?@'#?BGQSM<2PS+-Y7TOH%S+5I<9S(\8 M01<`=D_8T]L[3M-Q5(G[3Z7>I)"3VWA@1J.)JM5QT-TCFKPFR9'0=\RG1,5U M*!:V;.]2J$[2+A!O$D%4WL'8(]:/=^R+A%=-N_;%6!9JN!1.VE3/J:0D=)V98T/D^S,UUE M`CXZ'N*#/^953_"J ML]2>2TV?&%3;\+'B+Y">0'C;HNL9'Y"M3XD0%6VJ9S]_G]%:7UQ&3LLPIE*G MU;>Z/5M;S]@#YVTL*300.U56]#,O=42^DI:@56J]X::$54LUL^FLY]1E7LC0$1?]%L%A&C2U+L+I)%^S:P[ER9%V*Z2A`35$D`5YK4<[0*M'!7$?.#EE M!P_P2RRML:AG.:9-CU+I=9C@4^4AJ[7]@RR/C61%%CJN'"A&Z("HLJ@OU9:".B+SZ/JP/TF7#?_=ZSS_W$WWJ MKN:UX_A*=#]9E^3'`#^Z7*+]QL4Z.41>*Z'RO>*RR[OX\.$7D/XM,9N/Y1<: M^(_&F3O#6DJ!'6B[YC3K[A76IBM0LR*K4$ZYK]= MCSJJJ?=V\)MU`_!+\@-:C?<<0$Q.T=\FSO%Q?N!719OL[Q55THUC4/0;[>M@IF0,JD1 MHH,'B:*[!H;K/--?^J1XUY7P_P`L\8?&[%H7["SG*\=Y(P$,BJ*:DC+//M'& MW,Y:9]RDFB1_9K9,K+R$BX`A`6=N#B4I">DA8*F,UJ2K/_\`_$7JWZE3^TJ^ M_B",;&O*CFM+MWMHRS61V3)G)Q4,Q03LB=5LC(@D)))-7)R.WL(9)%(Q"+J& M6)^*`]PZPAM/_![GCAF^.LC/+CI(\?,CAXK]''?&!OSLWRV?PE763XL7DFBF MLF`W$#SQC+FU:R8..EU#?`B+=ND8YA'X`4!'JKG-8TO<:-`J3[`OHL[2YO[N*QLV M.DO)Y&QL8T5)95!_F;S"WWRH\FX'/9)X-'#SK^D[H+T,Z:]F_2.YW/NF2UCW)#8FXS65>W4YM`"; M6V.GU&V['%L4<,8UW,WON#G.8UCSM;X=67P\8K2M])EM?Y#\AK4^7AW>SV%B MWL6&<5YADVXR#S3U"*QPGPHT\2X^#W4%?`\:R#=L4K9-TV]Q,J::Y$D^8 M[3S[\U9N9=4^_0D!Q'#4#R=3P)H00.%1[:+H+WR=L.-[>=^6E_LT2_Z\F1T;]+R]T;GNE]ZY8NCJB>\V]M2JOC=W M9$9%>.=VUWG5-8@@0QQ?GF=%K"DA&*B!3`FW>P;)V50P]@]'<.X"(=<6WG+Z M6WIQ6A>6-^6KQ4?.*KNE^'SA79GNLVY)Z398;)E]=/J?@]*QN`R0>;F3/C+1 MYT-."8C]-I4U&6*Z($&,CL78^G<1%GTTE=\0:W9'C5E(/&,=/0,P^02<)I&^7>F04.`I%4`WV@5"U'"-QK5.?_.R_4@_\%ZO_P![NF?ZT>E2 MHTQ^:RX_RO\`U'"\C&MWGAD@&S)Q(L&[UR%>TL!:LEWB*3QR`FT\Q0%NV.8_ MQ`0_%_`/2I30SS69Y^:+Y*O(-KF1<`.,?&O5HKB^WN%*F-?Y"2D22,R^TWF3 M50-'.)*1/(HOW>88RQ=GD'0E1$LE-`4$BG,R;J&&IX(S2WWB>*L><*^(N5<% M^-.7\9<>CP;U7.X--N_F5T44IBZVY^/SMNO=C41*`.)^V3BJSI<>XE2*28'1UO)%R7\! M_+3B'R7XC[["/FDUU M$S.`;H/0,8SI4B4<:*WNAX(/!.5^F.XO\B.*7"K9J)R3QR[XI2L@]2M- M4R?*SX_.9W%[RR8GY2O'!@ESVY>V2J%KV7.<[;-O4E=(".;56_1]@0!_'*I5 MC=LY>^TJN3W!3F4'3@_8ZB0C4CC4+6:X%NEQ4WGF.S_5>4WB)Y(4O&\HOUFU M/52H MS@_BJP'C=U7SX>,GC]*<=LC\2\]H56E=+L^H+3NC5NU$GTYBTQ5;B7D*6MY+:)]-9G'7]2IS#H:\86RYU'B`Z)K+>D MM7A"D[H*R0*M@6`I3)*^H""J4TQ^)3AOI^?"]OW!*]:[RXY@R\.SWO6JU)4: M(S>`FV%I^[%?GK1&72VVFY6F&4&"D;?;+!%-_2T8"NU9-TC&%8ZBXIH`*<2D MCP1I'),B\9'`OFAE/U!>]AV;:FRL??+5,NZ8[9 MOTY%9=1&S-5R*-1%(/64P=^W0#BIS..T72 MZVYRBQ6/-G2BA>-WB:C951(%B MN1!`0:U"ACVZ=+E]L/+!]26@Q9(/O#57I%ZBT;I/)`*EI4>#YTFD0J[P&!-6 M<$9`Y5`3^T"AP3[^D##V[]*E-,?FLO\`.R_4@_\`!>K_`/>]IG^M#I4IIC\T MR17QJ^7OS/<[?IG$CB[2KA#/("TU3CGB=7M->E$B)R$+/P69UF)FX:11*90A'D M;(M54%B@)@`Y!#N/5EIGFJ4_DY\0?//A+S=MG(WQ&T?6WV;\D:?HS*:K^`(M M6,MCKFZ-$F6D9VNP;R$8@E1;&[D"S%9.DF3[*>)>VB!%(]NL>I!KP6LU[2VC MO!6'/!-XJ(SQK<7&S[08:'6Y7;9]`K*PE+;K M"=Z*9@2>32SE;\=,$!+(%%IO=J/#DHKOJJ.$?+OEY9.';KB_QWTS=6])IG(% MC;EL^B6LF2NO+(^RM2!;28N7[+V598D0Z%$`]7J!`_?MV^,$*T9`K535_P`3 M.K?O`L?Z)'^)G^M4O\:W[P/V_P#*/^I?K?Z;J?U*M1_TE7^\I&?6G@AY0ZYR M9J4ST-)1S?5JGZB@1+YEX_35652$?BVFD^_P$>L-; MF@EP>Y6Y&(?5/>)6_*"-;?G/'Y'+]!'9YN;#=QW9_==)?4O4*+)I3-.O]9AK;6Y)(2]G41. M,47[,RA2F."+E--8"+)B/J25*8AOB4>LP6UQ%=V[+F`UAD:'`^PBJ\%=V;7S M6R=SY#:&XX3!G<9=RVT\9^C+"\L=0\*M)%6NY.:0X<"%H]RH+G5L5US,&;PT M>\T3,[U2&C\JOL"S=6FLR<(V=>][:WM`@L]*83>@W8`[]A_!UIWL!NK.6V!H M9(W-K^\"/YUN'3OXCE^W?AALUUB[ M6?X_TJF?DL(+NTRKVVOUGWS'-9+5[0TU>+=TD=P]@!+?1>2T.C-++OF,U+.< MX\?F]Q=]=QQY#3:R.>4"`=>TL]GKO,NFJL0I&M5$U1,>LBU&646[%!L1EZ_6 M4_M]\C;NNK>WP,[9R-4K=#1XEQY4^3XJ^%%Y+]B>S]T[J[FMMWFVV2BVQ%W] M]O)FU#(;2)KA*)'`CA/J^[M9Q+S+ITENJD2'TWF*W1M-E%$W;TG*)L8]0L@TB'%L/O5]1X_,P?/[Q_(O8 M_P#"LZ5W#)-P]9[@'$N9<7SQ7Z+`RV9J^&KGBM6FDS7BYXX. MN+O"/%\[FV9V-SFH=?2;^V5(=)=K;]"6^\+R+<9A8;=XI,X:W?O.XT^84'S+H7WA=58>L'<'G]T8^028&WG%C9.!J M'6UD/1;(TCFV=[9)V^R4*07K?EUD1T1'1$=$1T1'1$=$1T1'1$=$1T1'1$=$ M1T1'1$=$1T1'1$=$1T1'1$=$1T1'1$=$1T1'1$=$3"_(MPAKO.WCS*YBX>,X M#0:Z\-;LDN+M(3-Z_=6K)RT2:RQD4%GJE7L#1R=I(I(_C^@Q%B@91!,.MCW! MA8\YCS;$AMPTZHW>3J>/[)Y'\O,!=D>UKN$RG;EU0AW=$R2YVQ=1_=LE:M/O M36KGM<71U(8+B%S1)`YW"H=&2&2/4*WA_P";TMQ7O%G\;?,$Z^=S-9NTE&9/ M+6IRLA'P-CE'WK?YHY?.2$9MZ[99!896MO\`U%:/#/E$RF[+-@'ANTLT[&3. MV[E_JWM>0PNY`D\65\B?>8>1K[0N_O?)V]V763;MGW6]#`W*6-WCV29&.W:" M^:"-GN7[6-)!@^[WT-#)$(6O(]R8BT[UDY>.*KT>9N@\&8*R99<;O@LMM M',+0)4L9F&39O(2]W) M!@.AF,A]3(9*^9%.S%%^IY_AGWA[8H;J8:G.UZK6($SRQF7TQ)'[LV`W0;WA M_(;S4W#4(^BWV?:U&EY)B\$9?.<1@E#QR9&&HW!E(J0.6UD$W#8564,K+6*4 M3;+'6>&51/UL-Y83>O!?[Q?*(9':6LC'N1CAP>ZM&-Y<&ZGNH:FH79K874K` M?Y=>/M71B;(7%6OTRW3;:QMW2,#(`R M1JMP9G4,^H6?4^GY1"5ZNYM!0$:U\4"KL#Q7RHF17;NTEO>%? MU',X.H*ISG.^SF]+B MZNMUW-R]UU+<%QG=-6CQ)JXAS2-&B@#`T,:UH:`$.YC\NLPX68C8MDTMV=;Y M4OV73JDQ.D,]>K@\(8L17(=`YR]BJ*_LCQR;]B9,R*+'^!0*;XLOE;;#V3KR MY/+@UHYN=X`?SGP'%9#Z$=$=W]?NH-KL/:3`W6?4NKEX/HVELT_63RD#P'NQ M1CWI92V-O,D5P_&%P^U?GSRBF_([RK8NB49"^#>Z5%OV[DT7I%WCG*GW?85U MO)N5':64Y09HU3:&,51!\NU2;D$Y$G76/=M8BZSN3=N'*`^@)-30>3W#D!7Z M#.%/`D`>!7JKW>]C4C#N)V-^YWT>L^=T;0TY'(Z MI'2`$/B9(^5P:Y\*MS=967B*H[?*>E8I3AO:*C2[Y*9O?-#U7C?GM`M$%9Y" MHSB%TMW(?,8JOLHJ8BGT?)^\_>*@FLW15`73054C`*9SAU!5F\ZJ'7*=[Y+6 MGAEYT[)MX:+E>PEQL_(1C3IVVSJ%NX]*Z]Q`7DJ_E\(F`QZM(4HD=2&;P/DA M1'[3?.%@'OZ3C'FKT%6TY+J;O'YHAX_^#]4L5E;9!F6A^0S(ZWN"M4/XY+!+,&:I^-YM=T;()'?Q;S4X MI+$C$]VCM1&M5YND#8RY(Y=P@(D,HF"[Q4T&CV\U(?P=V2N2/(;R*Y;9-9A) M"^,>F2$NK-L:FW?N7KGLT;$9%7.X4#\<5 M1Z!0X2.B5?3)_$"FFJ)Q^MEOQ"E M3NP5R9@9&L1%BM[5V^*R!TB65>0Z!!,()"FH/YD9R)'Q*.2UVODCR>\=7A4C MK9$ZQJ.N;M8M!@9:NQ/("V\:[7JS:$XR;QX\>*E?NEYTCD?_`+#?(EH^U.I[ M];>/U8K&_41QQ+K;+EG=V5=EHYWJ,+0+',/7A*PJS?J2IY3T'0!,5SDE0".) M\*I%/,!L.E4WD7R0&V3TP\B(&M+PCEN^1:QN8@PM32O:'6]XA*DM4C.9)BNQ9.3 M(_,KI>XF)GB@'N_E4GMTP.A2?FBRNPNIK6"+R/$#3]\>5EENVRQU`=:?FFM8 M%E]1L*V9L;TWH:C*/IMJ?MEH_P"SOLUZLY^9@[3.3G M(/!LC8:Y-RNCQ'G-YQK7?,&]_DG=UCL'BC0E*^X8?- MM@A$OF8Y1'L)VPB_6IIPK^RFWY=OO)2N>0NA8];[-HMDPS;O-#RTL62W1.R3 M3F%I:N,T'DS0M,XQVE09(P!59-$*Y;ZW%*@9D59O)>TB46H"2/%20--?&BD) MXZ9AD6QT-&5RE-3 M7IB:]_[&&-$BJ:LF^VK;Q8)R MM8@MFG*"[DFN+\?5..B5EL6-;_P]960<]/1YT]6?V"&NGR)GJ=[3,\?+!IL2_S';9!: MFFU>"GZR]K,8L\BT'K@WS9"J$9>D"G.)"B*,Y_,F%\P(32LJJ?BEXI\T^2MQ MHN4K8=R=<,X&PG,7JLUM["5K=CFBP(.9B19$>JH+V>0KZ M3MRDL/#P]ZOME&Y#:S=+%QUV[4]ES?']JNF`ZO MH04#B7(6QAI3ZQUFPUR=F):#;QZ%M68!\PL]6$XI-%3""!GDI``+@$]G5LBJ M>Y5+P;W&];9J6M36N268Y?H.JY[N6RY9"[G44N(&S[*>?E:_0+]7XYS(V+1* MFQEEGBJ9I0Q4A:K+"B91(95*T)"6?/J9;-!\UO)^QR%5L]OH^)4KC:I%VXW* M#4:;!9#,7#&+^8\6RXSPICYSJZ-^<]C.GTH=`\8JF19--90A1*\4^@H]O'3N M.HSW.7BM,O-BTF[[MR.NGE6A?(1C$YI=FLU>QZ#P36R1?'19;&7\L_A<*;TY M1O'P$(=NV9?:#*64()W0J`H6!S5G`:3Y<**73QIZY1=(XYZEG]OV*$M-WB>1 M'/=I.CQ8TR5WB_L.-O(+G_J='Y?[`3D=H))@U;B9CD(XSNAV; M?37U:T42L6VP4JLL54491D5RD"29%$11OY M8_[.?^,NX?HQOY8GZW^WO_W(_;_Z?J.*O1OEX?G\EZ8/5U\RCWYY>-W!^>U7 M9(WM%W3M-K35VA2=9J[=K]X8@CD"F&)G6BQ2M[95CKIE.9BY,0Z1O4=LLW4, M8X[!G-NV.=B`GJRY:/=>WF/8?Z3?8?F(*[.]M_=;U([;-U>;D M95_D%A*+FQZO4X%!9NBU2N=/?+$G+`UBVB@)E!=,'!`#^V3L"`'6R6]WN+;P M%ODXG7F.:*"6+B]H_::>)`_+^T5V.W7L7M1[IYI-T]'\Y:[`ZK73B^;"Y7+ODSF45:(;CW6<;H MV;[`Y?Y9>WJD1H3:$CBRDW&V.-CO6R76.7VW2?XQ#>H=:UR>`O M,U_%CX MREW?8QK,A:7\`M;>*S8);)TK_3B?!//25C0:PNX.%`][D[L_"&^XGHN5[9R% MP)C2=*IEEK4DE,ZC2@,HBI'F,+Z-0)-&=K2<&Y%%VW%`IEDW"29B!ZP+UO62 MO,+/9R6M[<0"&1A!J]OES''F.8IXKKWTAV#W";;Z@8K>73_:^Y9-P8F_@G88 ML?=\"'_`\F+2(YFZHWZR&.8YP=[M5'AFODI84/"\=XT\-LYTWR$;=G.8TK.I M.\T.HV"L8BA,UFO,(!2:FM$L$/$M3P23QF)4C()$1502[G`I[0NT.[.TZYW)U%SO5GKOE<1TPZ?97+W M5]':7ES#<98Q3S/F$45E#+(X3%K@7![BYKW>[%)R7.9CXI=SY8Z_$\I/*?H+ M"UV!@9L:K<:J(HE]Q*S"-G82+.KSTHV779)097)S@\C8TSA20$0.[E'`B?H[V;XR6RQD@= M]XSMX#]\N)7-T.N(8W`/,VD#TIYPP0_#!9Q`-B8R!@(N/A(.%8- M(J'AHEFWCHN*C&"";5C'1S!HFBU9,6;9(J:229"D3(4"E````ZYXQC(V".,! MK&B@`X``<@!X!>9E]?7N4O9LEDII;C(W$CI)99'.?))(\ESWO>XESWN<2YSG M$DDDDU6RZLOE6GFJ[7[*@R;6*"AY]M&R\58(YO-1C*5083T"]1DX.;9)/D%T MVLO#2+=-PT9DWAU3-$TGOOID;&%(``@B7HB3\O&CCB2AJY83C_B1,Q6G M!LZVOL'134\_%=!9,4QJY M5:OT:WY)F5JI5369.*K3[)0JK.5:LKQK1:/CEZ_7Y.*=1,,LP8.%$$#-D4S) M(G,0H@41`25*V<[EV9VBUU6]V;.J+8KQ1?F/N3D-0?MSTRN'0>Z8V=-GS M;1':1HT4W-Z;O62*Q)E5+0*J[6;.7=9N];AK77W3ADJ5PS<.(:>9OXY99HN4#I',F)DS M@`E$!Z*.2SEZI5G*U:<.:U`.'%,6.YIZZ\-'*K51PI%.H%1>M*J-C'@EE(-Z MLR,9J*1A:+'1$?;.8HD7[KUZ`=3L=:','#N++#QTG$1%B7C&2T[%Q,TM'.)F M+CI91`S]C'2SB(:*.D$E"IKG:HF.4PID$I%H;/F><7:9JUCN>?TFW6&C2!Y: MDSUGJD%/3-.E%`("DE5I258.WU>D%`3*!EFAT5!](=Q^`=$J5]3.;9U8UIUQ M8:#2YUQ:&U=9V9>9JT'*+6)G4))69J;6=5?,5SR[:L2ZYW4<1P*A63DYE40( M<1-T1;P]=KZD^WMBD%#GM+2'=UYK93QC(T^V@)!XRD7\&WF3(#(HP[V0C6ZZ MS8J@(J+()G,43$*($7/MQ34TIX+(2SV@HJ-54:/3TE6-ND=`9* MI5J%349WR81D6TO=FIR,@,WMTJWF':;F2((/%R.EBG4,"AP,4+"KF5YA3I^V MVNHYQ0JM:;\Y^=O=EKE/KT'/W5Y[[MU\W;9F,CFLC8W/S+]=3W'BBQO6LH;O MW.81*:E8,WC&/6:BQV76/)\TL&9Q!8\D3G%EK8@P3GI&)06:I'(V6<'1*9,H@4!*'8HJM]+5 MZOSYX=6=@X>:5KTPWL,`I+1C*2/!V!HW=LVLY#G>(+&C)ALT?KI)N4?0N1-9 M0H&`IS`)%I;SG6?:?"%K6ET2FZ'7"/VU*JR3R"D9&LU^0D*N202K+Y[#1SIY74Y:.-#RJ M<$Y7;*+Q!)*).+5P#C9B:L, M=!0S"?LI8PECG&46R:S$^2%;JM(8LU)H()O94L2U7.DV!7TL$[+8F+%"7G2,B_!$'2R MH)A^M[=$JN=KV$8?49RVV>J8UE-8LM^;OVEZL->SRHPLY=6LJZ4?2C:VRT;# MMG]C;R3U8ZS@CQ18JRIQ.['_NK?G_25^8KJ1_QG>?* MS^[8E@Z^M<&1T1'1$=$1T1'1$=$1T1'1$=$1T1'1$=$1T1'1$=$1T1'1$=$1 :T1'1$=$1T1'1$=$1T1'1$=$1T1'1$=$7_]D_ ` end